Companies

Uniphar plots further M&A deals and reiterates medium-term target to hit €200m in profits

The listed healthcare group said it achieved steady growth in 2023 and is forecasting double-digit expansion of its new pharma division this year

Uniphar first listed on the stock market in 2019 and its shares have more than doubled in that time to value the group at more than €700 million